Compare Skyworks Solutions Inc (SWKS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Skyworks Solutions Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Skyworks Solutions Inc trades at $76.41 (market cap $18.01B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Skyworks Solutions Inc is far larger — about 3.7× Travere Therapeutics Inc. Common Stock's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Skyworks Solutions Inc for 50 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SWKS | TVTX | |
|---|---|---|
Market Cap | $18.01B | $4.88B |
Volume | 4,074,606 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $91.45 | $67.52 |
52-Week Low | $52.50 | $26.79 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $17.89B | $5.01B |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Skyworks Solutions (SWKS) trades at $76.89, up 2.93% with a bearish technical signal despite recent earnings beats. The company shows declining revenue and profit margins over recent years, with 2025 revenue at $4.09B and net income of $477.10M. The pending Qorvo merger dominates news coverage, with analysts projecting significant synergies. Current valuation metrics include a P/E of 39.68 and P/S of 2.87, while cash flow trends show recent negative net cash flow of -$207.30M.
The investment outlook balances merger synergies against fundamental deterioration. Analyst consensus favors Buy (60%) with a $79.70 price target, but declining profitability and bearish technicals suggest caution. Key risks include integration challenges with Qorvo and ongoing margin pressure, while the RSI near 18 indicates potential oversold conditions for tactical opportunities.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
